Mologen AG provided earnings guidance for the year of 2014. The nine month report published confirms forecast for the year as a whole, as stated in previous quarterly reports. The Executive Board is expecting the net loss for the year to be considerably above the comparable figure for the previous year on account of the increased R&D investments.

The company said considerable progress has been made in the clinical development of the cancer immunotherapy MGN1703. This included the launch of a randomized trial in the area of small cell lung cancer as well as a phase III pivotal study in the field of colorectal cancer. In addition, the company presented EnanDIM, a new generation of immunomodulators, to the scientific community for the first time at the beginning of October 2014. These advancements are reflected in the increased expenses for research and development activities. The IMPALA study will include 540 patients from eight European countries. The study is being conducted in cooperation with globally renowned oncology experts as investigators. Patient enrolment for the randomized IMPULSE study, which was launched at the end of the first quarter, continues. The study is investigating the efficacy of MGN1703 in the indication of small cell lung cancer.